IngredientsSalba oil is the cold-pressed or supercritical CO₂-extracted seed oil derived from Salvia hispanica L., a member of the mint family Lamiaceae (order Lamiales, subfamily Nepetoideae, genus Salvia). Salvia hispanica L., also known as chia, is an annual herbaceous plant originally from southern Mexico and northern Guatemala; it belongs to the order Lamiales, mint family Labiate, subfamily Nepetoideae, and genus Salvia. The oil derived from this plant is marketed under a proprietary trade name—Salba—that refers specifically to a selected cultivar or cultivar-group of Salvia hispanica bred for a more consistent and elevated omega-3 content.
This trait has been selected by some cultivators with the brand-name Salvia hispanica product Salba (Salba Corporation, Buenos Aires, Argentina, Agrisalba), which has a more stable content of omega-3 fatty acids, especially α-linolenic acid (ALA), than generic Salvia hispanica seeds. The name "Salba" thus functions both as a proprietary crop variety and as a commercial ingredient descriptor used in peer-reviewed research. Other names used for S. hispanica are Chian, Salvia chia, Salvia chian, Salba, and Black chia.
Chia seeds are generally very small, oval-shaped, 2 mm long, 1 to 1.5 mm wide, and less than 1 mm thick; the color of the seed varies from black, grey, or black spotted to white. Salvia hispanica L. is mainly grown for its seeds and produces white and purple flowers, which are 3 to 4 mm small and hermaphrodites.
Significant differences in palmitic, stearic, oleic, linoleic and alpha-linolenic fatty acids between oils from seeds grown in different ecosystems have been detected. The Salba cultivar selection was specifically designed to reduce this environmental variability and produce a more consistent ALA-to-LA ratio.
As early as 3500 B.C., chia was consumed by the Aztec and Mayan peoples of Mesoamerica, and it became a hugely important Mexican cash crop from 1500 to 900 B.C. along with maize and other grains. It has been considered as a part of human food for about 5,500 years.
In pre-Columbian societies, chia was the second main crop after beans. In Aztec communities, chia was used for food, cosmetics, and religious rituals. Chia seeds themselves were used for culinary, medicinal, cultural, religious, and artistic purposes. The seeds were offered to the gods in religious ceremonies and given as tribute from conquered nations; Aztec records document that 21 of the 38 provincial states gave chia seeds as an annual tribute to rulers.
Chia was of economic and cultural importance for the Aztecs and probably also for the Teotihuacán civilization that preceded them a thousand years earlier. Our knowledge of the pre-Columbian uses of chia depends heavily on the Codices (handwritten books describing pre-Columbian customs) dating from the 16th century and on various 16th and 17th century texts which discuss the history and culture of Mexico at and soon after the Spanish conquest. Most interesting perhaps is the Codex Mendoza (1541), which contains the pre-conquest Matrícula de Tributos, listing chia as one of four food tributes (together with maize, beans and amaranth) paid to the Aztecs by tributary states.
The Mayans used chia as a medicine and the Aztecs used it as an important food source. A common practice in pre-Columbian Mexico was to make flour from the seeds, known as "chianpinolli," which was incorporated into tortillas, tamales, and a drink called "chianatole." The common name "chia" is derived from the Nahuatl word "chian," which means oily; Aztec warriors and messengers relied on the seeds for sustained energy during long journeys.
In the sixteenth century, the Spanish conquest of native civilizations permanently altered Salvia hispanica's importance as a domesticated crop. Although chia was an important crop during pre-Columbian times, its cultivation decreased following the discovery of America; until recently this species was cultivated only on a few hectares in its native location. It was rediscovered as a nutritional crop in the latter part of the 20th century.
It is important to note that the traditional use of chia centered predominantly on the whole seed as a food and medicine. The explicit use of an isolated seed oil fraction as it is commercially produced today is a modern development; traditional preparations did not separate the lipid fraction from the whole seed matrix.
The seed of Salvia hispanica L., commonly named chia seed, which is rich in fiber and minerals, contains the richest botanical oil source of ALA known to date. It is characterized by high contents of polyunsaturated fatty acids, mainly α-linolenic acid (ALA), which accounts for approximately 60% of all fatty acids; linoleic, oleic, and palmitic acids are found in lower amounts. Chia seeds have greater contents of omega-3 acids than flaxseed.
The specific fatty acid composition of the patented Salba oil is as follows: the seed oil comprises from 60–88% PUFAs in a ratio of from 3.1:1–3.3:1 of alpha-linolenic acid (ALA) to linoleic acid (LA), 4–10% of C-18 mono-unsaturated fatty acid, 1–5% of C-18 saturated fatty acid, and 4–8% of C-16 saturated fatty acid in a mixed triglyceride form.
Chia and perilla seeds contain 25–40% oil, and α-linolenic acid (ALA, 18:3Δ9,12,15) proportion in their seed oil is the highest among crop sources (about 60–71%). ALA is known as an essential fatty acid for the human daily diet because it cannot be synthesized in the human body. ALA has a wide variety of health benefits as it is a necessary substrate for the biosynthesis of very-long-chain ω-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
In addition to primary metabolites, some secondary metabolites have also been detected in chia seeds, mainly compounds belonging to the group of polyphenols found free or bound to sugars. The content of phenolic compounds has been reported as ranging between 641.7 and 921.1 µg/g of chia seed extract expressed as gallic acid equivalents. The following phenolic acids have been identified in chia seeds: gallic acid; caffeic acid; chlorogenic acid; protocatechuic ethyl ester; rosmarinic acid; rosmarinic acid glucoside; vanillic acid glucoside; and salvianic acid A and salvianolic acid B/E, among others; the flavonoids apigenin, kaempferol, quercetin, and myricetin; and the catechin derivative epicatechin.
The stability of the resulting oil at room temperature is explained by the available levels of the powerful natural antioxidants found in Salvia hispanica L. whole seed. Salvia hispanica L. has a measured ORAC number of 3000 micromoles TE ORAC units per gram of seed and is known to contain such antioxidants as myricetin, quercetin, kaempferol, caffeic acid, and chlorogenic acid.
Chia seeds have high contents of dietary fiber and proteins, rich in many exogenous amino acids. Moreover, chia seeds have high contents of polyunsaturated fatty acids, mainly alpha-linolenic acid. These seeds are also a good source of many minerals and vitamins, as well as bioactive compounds of high antioxidant activity, particularly polyphenols and tocopherols.
It is well known that Salvia hispanica L. whole seed, unlike many other seeds bearing PUFA-containing oil, exhibits a shelf life of at least 5 years due to its structure and the naturally occurring antioxidants available in the seed matrix. However, once extracted as a pure oil, the isolated Salba oil is highly susceptible to oxidation given its extreme PUFA content, which is why the patented manufacturing process incorporates added antioxidant stabilizers. A peroxide value of the seed oil is maintained under 2.0 meq/Km in the stabilized commercial product.
Chia seeds contain high amounts of omega-3 fatty acids, specifically alpha-linolenic acid (ALA), which serves as a precursor to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the two most extensively researched and recognized omega-3 fatty acids. The key biosynthetic enzyme involved is omega-3 fatty acid desaturase (FAD). Omega-3 fatty acid desaturase (ω-3 FAD, D15D) is a key enzyme for α-linolenic acid (ALA) biosynthesis.
However, the conversion of ALA to EPA and DHA in the human body is limited. Once consumed, ALA undergoes enzymatic conversion in the body to longer-chain omega-3 fatty acids, specifically EPA and DHA. However, this conversion process is relatively inefficient in humans, with conversion rates typically ranging from 5–10% for EPA and often less than 1% for DHA. This conversion tends to be slightly higher in women than men. This limited bioconversion is an important consideration when comparing plant-based omega-3 sources to marine-derived options.
Although humans express the enzymes necessary for the conversion of dietary ALA to other members of the n-3 family of PUFA, in populations consuming typical Western diets the consumption of foods or supplements containing ALA results in limited accumulation of EPA, DPA, or DHA in cells and tissues. Since the beneficial health effects associated with the consumption of EPA- and DHA-rich foods are largely associated with changes in tissue membrane fatty acid composition, most of the health benefits attributed to fish and fish oils are not attained with the consumption of vegetable oils containing ALA. Although some beneficial biological activity has been associated with the consumption of ALA, the associated health benefits are not as well established, and health benefits would be largely independent of its conversion to longer-chain n-3 PUFA.
Chia seeds have gained attention for their potential anti-inflammatory properties, which may be attributed to their high content of omega-3 fatty acids, dietary fibre, and antioxidants. Apart from omega-3 fatty acids and fibre, chia seeds also comprise polyphenols, which are plant-based substances possessing antioxidant and anti-inflammatory characteristics.
The antioxidant capacity of chia seeds is defined by their ability to inhibit the synthesis of reactive oxygen species (ROS) or through direct scavenging action. These antioxidants can transform into active molecules, reducing cell damage and playing a role in regulating gene expression and signal transduction.
Proposed mechanisms include improvements to insulin sensitivity, inflammation, hepatic steatosis, and cardiovascular disease (CVD) risk factors, although the health benefits of ALA are not as well established as those attributed to EPA and DHA. The ALA-rich oil may modulate lipid metabolism partly through its high proportion of n-3 to n-6 fatty acids, which can influence the balance of pro- and anti-inflammatory eicosanoids.
The landmark human trial specific to the Salba cultivar was conducted by Vuksan and colleagues at St. Michael's Hospital, Toronto. The objective was to determine whether addition of Salba (Salvia hispanica L.), a novel whole grain rich in fiber, α-linolenic acid (ALA), and minerals to conventional treatment is associated with improvement in major and emerging cardiovascular risk factors in individuals with type 2 diabetes; using a single-blind cross-over design, subjects were randomly assigned to receive either 37 ± 4 g/day of Salba or wheat bran for 12 weeks while maintaining their conventional diabetes therapies. Twenty well-controlled subjects with type 2 diabetes (11 men and 9 women, aged 64 ± 8 years, BMI 28 ± 4 kg/m², and A1C 6.8 ± 0.9%) completed the study.
Compared with the control treatment, Salba reduced systolic blood pressure (SBP) by 6.3 ± 4 mmHg (P < 0.001), high-sensitivity C-reactive protein (hs-CRP) by 40 ± 1.6% (P = 0.04), and von Willebrand factor (vWF) by 21 ± 0.3% (P = 0.03), with significant decreases in A1C and fibrinogen. There were no changes in safety parameters including liver, kidney and hemostatic function, or body weight.
A 2015 systematic review evaluated seven clinical trials of chia seed supplementation in humans: seven studies (n = 200) fit inclusion criteria; of the chosen clinical trials, only one was not randomized, and five of the studies were blind experiments. One study showed a significant drop in systolic blood pressure (SBP) and inflammatory markers, yet there was no change in body mass, lipid profile, or blood sugar. In four of the studies reviewed there was a significant spike in ALA and eicosapentaenoic acid (EPA), with no significant change to other parameters. In the acute trials, post-prandial blood sugar was significantly lower.
A 2024 meta-analysis and systematic review included 14 RCTs with 835 participants: this review sought to investigate the impact of chia seed supplementation on obesity indicators and metabolic factors; through a thorough search up to April 2024, 14 clinical trials involving 835 participants were included. The findings revealed a notable decrease in triglyceride levels with weighted mean differences of -8.69 mg/dL and -13.11 mg/dL at higher and lower doses, respectively. A statistically significant reduction in LDL-C levels was observed solely in the higher dosage group, showing a WMD of -4.77 mg/dL. The decrease in systolic blood pressure (-2.78 mmHg) was statistically significant but was only observed with the higher dosage.
Evidence strength: The cardiovascular evidence is preliminary to moderate. The Vuksan 2007 study is the most rigorous Salba-specific trial, but it was small (n=20), single-blind, and used whole grain Salba rather than isolated oil. Broader meta-analyses of chia supplementation show modest and dose-dependent effects on blood pressure and lipids, but overall evidence remains insufficient to support therapeutic claims.
In the Vuksan 2007 RCT, significant decreases in A1C and fibrinogen were observed in relation to the Salba baseline. A 2017 double-blind RCT evaluated Salba-chia specifically in overweight and obese patients: preliminary findings indicate that consumption of Salba-chia, an ancient seed, improves management of type 2 diabetes and suppresses appetite. A double-blind, randomized, controlled trial with two parallel groups involved 77 overweight or obese patients with type 2 diabetes (HbA1c: 6.5–8.0%; BMI: 25–40 kg/m²). Both groups followed a 6-month calorie-restricted diet; one group received 30 g/1000 kcal/day of Salba-chia, the other 36 g/1000 kcal/day of an oat bran-based control.
People with T2DM and hypertension, maintaining usual dietary consumption, physical activity pattern, and medications, had significantly reduced systolic BP compared to the control group when having consumed 40 g/day of chia seeds for 12 weeks.
A study of postprandial glycemia found: a comparison of the effect of Salba-chia (Salvia hispanica L.) versus flax on postprandial glycemia and satiety scores showed that despite the similarities in nutritional composition, Salba-chia appears to have the ability to convert glucose into a slow-release carbohydrate and affect satiety to a greater extent than flax, possibly due to higher fiber viscosity.
Evidence strength: Mixed. Acute studies show consistent attenuation of postprandial glycemia. Long-term glycemic control (HbA1c, fasting glucose) is less consistently improved across studies, and one recent systematic review noted insignificant glycemic effects in some newer trials.
Chia seeds have gained attention for their potential anti-inflammatory properties, which may be attributed to their high content of omega-3 fatty acids, dietary fibre, and antioxidants. A 2024 systematic review and meta-analysis aimed to provide an overview of the current understanding regarding the effects of chia seeds on inflammatory markers, specifically C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α). Four RCTs involving 210 participants were included in the meta-analysis.
The Vuksan 2007 Salba trial confirmed reductions in hs-CRP and vWF. In the case of the emerging risk factors, a reduction was observed in the high-sensitivity C-reactive protein (hs-CRP) by 40 ± 1.6% (p = 0.04) and in the von Willebrand factor (vWF) by 21 ± 0.3% (p = 0.03).
Evidence strength: Preliminary. The number of eligible RCTs for meta-analysis remains small (four studies, 210 participants as of 2024). Most data relate to whole seed or ground seed rather than isolated oil.
A pharmacokinetic study in 16 female subjects measured the acute plasma response to chia seed oil: chia seeds are a rich source of alpha-linolenic acid (ALA), but the acute plasma ALA response to chia seed or chia seed oil ingestion had not yet been determined. Female subjects (N=16, 20 to 45 years) ingested, in random order, a snack cluster placebo, snack cluster with 8 g milled chia seed (1.3 mg ALA), or chia seed oil (1.3 mg ALA). Analysis revealed a significant interaction effect for ALA (P<0.001) but not for EPA (P=0.581) or DHA (P=0.445).
Blood samples analyzed for ALA, EPA, and DHA confirmed the significant interaction effect for ALA (p < 0.001) but not for EPA or DHA; ALA in both milled chia seed (↑82%) and chia seed oil (↑91%) increased significantly within 2.5 hours post-ingestion and stayed elevated above placebo. These data confirm that while ALA from Salba oil is readily absorbed into plasma, it does not produce acute elevations in EPA or DHA.
A study on chia oil supplementation during gestation and nursing examined ALA conversion to DHA in humans: the effect of chia oil as the main daily source of ALA was evaluated by measuring the DHA content of erythrocyte phospholipids and breast milk obtained from women who received the oil during a period of gestation and nursing; the study was a randomized clinical trial that included 40 pregnant women.
Walnut, flax, chia, canola, hemp, echium, and perilla seed oils are plant-based sources of omega-3 fatty acids such as ALA; however, they offer minimal support for increasing blood DHA and EPA levels.
Evidence strength: The ALA absorption from chia oil is well documented. The limited conversion to long-chain omega-3s (EPA/DHA) is consistently demonstrated across both human and animal studies. This is a key distinction from marine omega-3 sources and limits the equivalence of Salba oil as an omega-3 supplement relative to fish or algal oils.
According to recent research, chia seeds may improve lipid profile, glycemic markers, antioxidant properties, blood pressure regulation, and weight management. The 2024 meta-regression of 14 RCTs showed a notable decrease in triglyceride levels across both higher and lower doses of chia seeds, with weighted mean differences of -8.69 mg/dL and -13.11 mg/dL, respectively; additionally, a statistically significant reduction in LDL-C levels was observed solely in the higher dosage group, showing a WMD of -4.77 mg/dL.
Evidence strength: Modest. Effects on triglycerides appear more consistent across doses than effects on LDL-cholesterol, which only reached significance at higher doses. Studies specifically on isolated Salba oil (as opposed to whole grain Salba or chia seed) are very limited.
The 2017 Vuksan double-blind RCT (Salba-chia in overweight/obese T2DM patients) assessed body weight as the primary endpoint: the aim was to assess the effect of Salba-chia on body weight, visceral obesity and obesity-related risk factors; the primary endpoint was change in body weight over 6 months; secondary endpoints included changes in waist circumference, body composition, glycemic control, C-reactive protein, and obesity-related satiety hormones.
Preclinical evidence suggests lipid-lowering effects: a non-toxic concentration of chia oil extracts (1%) reduced lipid accumulation in obese worms, which was not caused by food deprivation, in a Caenorhabditis elegans model. These results remain preclinical only.
Evidence strength: Weak-to-preliminary for isolated Salba oil. The most relevant human data come from whole-grain Salba preparations. Effects on body weight in humans have been inconsistent across studies.
One study assessed whether chia seed oil affected running performance. Plasma ALA was elevated more than 3-fold immediately and 1 hour post-run during the chia seed oil trial compared to little change following the water trial; pre-supplementation and pre-run plasma EPA and DHA, and the overall pattern of change in EPA and DHA, did not differ between trials. Contrary to the hypothesis, chia seed oil did not improve running performance in this study.
Evidence strength: Very limited. One negative acute trial only.
The following doses are reported precisely as stated in cited clinical sources:
Note: The doses studied relate almost entirely to whole-grain or ground Salba/chia seed rather than to isolated Salba oil per se. Clinical evidence specific to Salba oil alone in isolation, with defined oil doses, is limited in the published literature.
Concerning the safety of chia in the Vuksan 2007 study, no secondary effects were observed on coagulation, on liver enzymes, and on the kidney, even at the highest dose of n-3 PUFA considered (37 g of chia). GI adverse effects are the most commonly reported adverse effect in clinical studies.
Caution is warranted if used concurrently with anticoagulants (e.g., warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel, prasugrel) due to case reports of enhanced anticoagulation and bleeding with ingestion of species related to chia. The omega-3 content in chia seeds may have mild antiplatelet effects, theoretically increasing bleeding risk when combined with anticoagulant medications such as warfarin, apixaban, or antiplatelet agents like clopidogrel or aspirin; whilst clinically significant interactions are not well-documented with dietary chia seed consumption, patients taking these medications should inform their GP or anticoagulation clinic before substantially increasing intake.
The blood pressure-lowering effects observed in some studies suggest potential for additive effects with antihypertensive medications, though this remains largely theoretical at typical dietary doses.
Contraindications have not been identified, aside from allergy to chia or related species. Allergic reactions to chia seeds are uncommon but have been reported in case studies; symptoms may include skin rash, urticaria, gastrointestinal upset, or in rare cases, anaphylaxis. Case reports of allergy exist, and Salmonella-infected sprouted chia seed powder has been documented.
Information regarding safety and efficacy in pregnancy and lactation is lacking. One randomized clinical trial did administer chia oil to pregnant women to assess DHA transfer to breast milk, but comprehensive safety data for this population remain limited.
Chia seed oil faces challenges in food applications due to its hydrophobicity and susceptibility to oxidation. The commercial Salba oil product addresses this by using supercritical CO₂ extraction combined with antioxidant stabilizers to achieve shelf stability.
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of chia seeds in foods subject to thermal processing. The safety assessment is based on previous assessments of chia seeds by the EFSA NDA Panel, information received from a public call for data, and information retrieved from an extensive literature search. The Panel considers that there is a potential for substantial acrylamide formation in biscuits with 10–20% added chia seeds flour with low residual moisture contents (≤ 2%). This concern pertains to baked whole-seed or flour preparations, not to the extracted oil.
Health conditions that Salba oil may help support.
Body systems that Salba oil may help support.
Go back